Sage Journals: Discover world-class research

Abstract

Inflammation has long been proven to engage in tumor initiation and progression. Inflammasome, as a member of innate immunity-induced host defense inflammation, also plays critical roles in cancer. Inflammasome is a multiprotein complex responding to pathogen-associated molecular patterns and damage-associated molecular patterns. It is composed of receptors such as NOD-like receptors and AIM2-like receptors, adaptor protein ASC, and effector caspase-1, which can process proinflammatory cytokines interleukin (IL)–1β and IL-18. It has been reported that upregulated inflammasome activity is correlated to various types of cancers including breast cancer, gastric cancer, brain tumor, and malignant prostate, while inflammasomes also have a protective role in colitis-associated cancer. Autophagy, an intracellular recycling process for maintaining homeostasis, is deemed to contribute to the underlying mechanism of its dual roles in cancer. It has been found that distinct tumor stages and different isotypes of caspases involved in the inflammasome pathway can affect the roles of inflammasome in cancer. In this review, we update the latest evidence of inflammasome roles in cancer and novel inflammasome pathway-targeting agents for immunotherapy and discuss future research directions of inflammasome-based target therapy.

Keywords

Inflammasomes cancer autophagy

Get full access to this article

View all access options for this article.

References

Balkwill

Mantovani

Inflammation and cancer: back to Virchow?

Lancet 2001; 357: 539–545.

Munn

Cancer and inflammation. Wiley Interdiscip Rev Syst Biol Med 2017; 9: e1370.

Grivennikov

Greten

Karin

Immunity, inflammation, and cancer. Cell 2010; 140: 883–899.

Dmitrieva

Shilovskiy

Khaitov

et al. Interleukins 1 and 6 as main mediators of inflammation and cancer. Biochem 2016; 81: 80–90.

Hoesel

Schmid

JA.

The complexity of NF-κB signaling in inflammation and cancer. Mol Cancer 2013; 12: 86.

Tilborghs

Corthouts

Verhoeven

et al. The role of nuclear factor-kappa B signaling in human cervical cancer. Crit Rev Oncol Hematol 2017; 120: 141–150.

Browning

Patel

Horvath

et al. IL-6 and ovarian cancer: inflammatory cytokines in promotion of metastasis. Cancer Manag Res 2018; 10: 6685–6693.

Harton

Linhoff

Zhang

et al. Cutting edge: CATERPILLER: a large family of mammalian genes containing CARD, pyrin, nucleotide-binding, and leucine-rich repeat domains. J Immunol 2014; 169: 4088–4093.

Kayagaki

Warming

Lamkanfi

et al. Non-canonical inflammasome activation targets caspase-11. Nature 2011; 479: 117–121.

10.

Kayagaki

Wong

Stowe

et al. Noncanonical inflammasome activation by intracellular LPS independent of TLR4. Science 2013; 341: 1246–1249.

11.

Dinarello

CA.

Immunological and inflammatory functions of the interleukin-1 family. Annu Rev Immunol 2009; 27: 519–550.

12.

Franchi

Warner

Viani

et al. Function of Nod-like receptors in microbial recognition and host defense. Immunol Rev 2009; 227: 106–128.

13.

Groslambert

Spotlight on the NLRP3 inflammasome pathway. J Inflamm Res 2018; 11: 359–374.

14.

Juliana

Fernandes-Alnemri

Kang

et al. Non-transcriptional priming and deubiquitination regulate NLRP3 inflammasome activation. J Biol Chem 2012; 287: 36617–36622.

15.

Ding

Wang

Liu

et al. Pore-forming activity and structural autoinhibition of the gasdermin family. Nature 2016; 535: 111–116.

16.

Miao

Rajan

Aderem

Caspase-1-induced pyroptotic cell death. Immunol Rev 2011; 243: 206–214.

17.

Perregaux

Gabel

CA.

Interleukin-1 beta maturation and release in response to ATP and nigericin. Evidence that potassium depletion mediated by these agents is a necessary and common feature of their activity. J Biol Chem 1994; 269: 15195–15203.

18.

Yabal

Calleja

Simpson

et al. Stressing out the mitochondria: mechanistic insights into NLRP3 inflammasome activation. J Leukoc Biol 2019; 105: 377–399.

19.

Gross

Poeck

Bscheider

et al. Syk kinase signalling couples to the Nlrp3 inflammasome for anti-fungal host defence. Nature 2009; 459: 433–436.

20.

Riestra

Valderrama

Patras

et al. Trichomonas vaginalis induces NLRP3 inflammasome activation and pyroptotic cell death in human macrophages. J Innate Immun 2019; 11: 86–98.

21.

Xiong

et al. The TWIK2 potassium efflux channel in macrophages mediates NLRP3 inflammasome-induced inflammation. Immunity 2018; 49: 56–65.

22.

J-W

Lee

M-S.

Mitochondria and the NLRP3 inflammasome: physiological and pathological relevance. Arch Pharm Res 2016; 39: 1503–1518.

23.

Zhong

Zhai

Liang

et al. TRPM2 links oxidative stress to NLRP3 inflammasome activation. Nat Commun 2013; 4: 1611.

24.

Katsnelson

Rucker

Russo

et al. K+ efflux agonists induce NLRP3 inflammasome activation independently of Ca2+ signaling. J Immunol 2015; 194: 3937–3952.

25.

Iyer

Janczy

et al. Mitochondrial cardiolipin is required for Nlrp3 inflammasome activation. Immunity 2013; 39: 311–323.

26.

Liu

Ding

L-H

et al. Activation of the Nlrp3 inflammasome by mitochondrial reactive oxygen species: a novel mechanism of albumin-induced tubulointerstitial inflammation. Int J Biochem Cell Biol 2014; 57: 7–19.

27.

Wang

Yao

Zhu

et al. Amyloid β induces NLRP3 inflammasome activation in retinal pigment epithelial cells via NADPH oxidase- and mitochondria-dependent ROS production. J Biochem Mol Toxicol 2017; 31: e21887.

28.

Legrand-Poels

Esser

l’Homme

et al. Free fatty acids as modulators of the NLRP3 inflammasome in obesity/type 2 diabetes. Biochem Pharmacol 2014; 92: 131–141.

29.

Chen

C-Y

Yang

C-H

Tsai

Y-F

et al. Ugonin U stimulates NLRP3 inflammasome activation and enhances inflammasome-mediated pathogen clearance. Redox Biol 2017; 11: 263–274.

30.

Shimada

Crother

Karlin

et al. Oxidized mitochondrial DNA activates the NLRP3 inflammasome during apoptosis. Immunity 2012; 36: 401–414.

31.

Mathew

Lindsley

Sheridan

et al. Degraded mitochondrial DNA is a newly identified subtype of the damage associated molecular pattern (DAMP) family and possible trigger of neurodegeneration. J Alzheimers Dis 2012; 30: 617–627.

32.

Misawa

Takahama

Kozaki

et al. Microtubule-driven spatial arrangement of mitochondria promotes activation of the NLRP3 inflammasome. Nat Immunol 2013; 14: 454–460.

33.

Hornung

Bauernfeind

Halle

et al. Silica crystals and aluminum salts activate the NALP3 inflammasome through phagosomal destabilization. Nat Immunol 2008; 9: 847–856.

34.

Caicedo

Samelko

McAllister

et al. Increasing both CoCrMo-alloy particle size and surface irregularity induces increased macrophage inflammasome activation in vitro potentially through lysosomal destabilization mechanisms. J Orthop Res 2013; 31: 1633–1642.

35.

Katsnelson

Lozada-Soto

Russo

et al. NLRP3 inflammasome signaling is activated by low-level lysosome disruption but inhibited by extensive lysosome disruption: roles for K⁺ efflux and Ca²⁺ influx. Am J Physiol Physiol 2016; 311: C83–C100.

36.

Orlowski

Colbert

Sharma

et al. Multiple cathepsins promote pro–IL-1β synthesis and NLRP3-mediated IL-1β activation. J Immunol 2015; 195: 1685–1697.

37.

Bueter

Lee

Wang

et al. Spectrum and mechanisms of inflammasome activation by chitosan. J Immunol 2014; 192: 5943–5951.

38.

Zheng

Tao

Jian

et al. NLRP3 inflammasome activation and lung fibrosis caused by airborne fine particulate matter. Ecotoxicol Environ Saf 2018; 163: 612–619.

39.

Jiang

Yang

et al. CLICs-dependent chloride efflux is an essential and proximal upstream event for NLRP3 inflammasome activation. Nat Commun 2017; 8: 202.

40.

Vande Walle

Van Opdenbosch

Jacques

et al. Negative regulation of the NLRP3 inflammasome by A20 protects against arthritis. Nature 2014; 512: 69–73.

41.

Mouton-Liger

Rosazza

Sepulveda-Diaz

et al. Parkin deficiency modulates NLRP3 inflammasome activation by attenuating an A20-dependent negative feedback loop. Glia 2018; 66: 1736–1751.

42.

Huai

Zhao

Song

et al. Aryl hydrocarbon receptor negatively regulates NLRP3 inflammasome activity by inhibiting NLRP3 transcription. Nat Commun 2014; 5: 4738.

43.

Zhong

Umemura

Sanchez-Lopez

et al. NF-κB restricts inflammasome activation via elimination of damaged mitochondria. Cell 2016; 164: 896–910.

44.

Bauernfeind

Rieger

Schildberg

et al. NLRP3 inflammasome activity is negatively controlled by miR-223. J Immunol 2012; 189: 4175–4181.

45.

Neudecker

Haneklaus

Jensen

et al. Myeloid-derived miR-223 regulates intestinal inflammation via repression of the NLRP3 inflammasome. J Exp Med 2017; 214: 1737–1752.

46.

Feng

Zhang

et al. Ly6G+ neutrophil-derived miR-223 inhibits the NLRP3 inflammasome in mitochondrial DAMP-induced acute lung injury. Cell Death Dis 2017; 8: e3170.

47.

Xie

Wei

Zhang

et al. MicroRNA‑33 regulates the NLRP3 inflammasome signaling pathway in macrophages. Mol Med Rep 2017; 17: 3318–3327.

48.

Guarda

Braun

Staehli

et al. Type I interferon inhibits interleukin-1 production and inflammasome activation. Immunity 2011; 34: 213–223.

49.

Rathinam

VAK

Vanaja

Waggoner

et al. TRIF licenses caspase-11-dependent NLRP3 inflammasome activation by gram-negative bacteria. Cell 2012; 150: 606–619.

50.

Tang

Zhang

Xue

et al. TRIF signaling is required for caspase-11-dependent immune responses and lethality in sepsis. Mol Med 2018; 24: 66.

51.

Guarda

Dostert

Staehli

et al. T cells dampen innate immune responses through inhibition of NLRP1 and NLRP3 inflammasomes. Nature 2009; 460: 269–273.

52.

Gaikwad

Patel

Agrawal-Rajput

CD40 negatively regulates ATP-TLR4-activated inflammasome in microglia. Cell Mol Neurobiol 2017; 37: 351–359.

53.

Allen

TeKippe

Woodford

et al. The NLRP3 inflammasome functions as a negative regulator of tumorigenesis during colitis-associated cancer. J Exp Med 2010; 207: 1045–1056.

54.

Sharma

Malik

Guy

et al. Pyrin inflammasome regulates tight junction integrity to restrict colitis and tumorigenesis. Gastroenterology 2018; 154: 948–964.

55.

Flood

Manils

Nulty

et al. Caspase-11 regulates the tumour suppressor function of STAT1 in a murine model of colitis-associated carcinogenesis. Oncogene 2019; 38: 2658–2674.

56.

Dupaul-Chicoine

Arabzadeh

Dagenais

et al. The Nlrp3 inflammasome suppresses colorectal cancer metastatic growth in the liver by promoting natural killer cell tumoricidal activity. Immunity 2015; 43: 751–763.

57.

Rawla

Barsouk

Epidemiology of gastric cancer: global trends, risk factors and prevention. Prz Gastroenterol 2019; 14: 26–38.

58.

Bhagat

Cui

et al. Overexpression of interleukin-1beta induces gastric inflammation and cancer and mobilizes myeloid-derived suppressor cells in mice. Cancer Cell 2008; 14: 408–419.

59.

Deswaerte

Nguyen

West

et al. Inflammasome adaptor ASC suppresses apoptosis of gastric cancer cells by an IL18-mediated inflammation-independent mechanism. Cancer Res 2018; 78: 1293–1307.

60.

Pachathundikandi

Müller

Backert

. Inflammasome activation by Helicobacter pylori and its implications for persistence and immunity. Curr Top Microbiol Immunol 2016: 117–131.

61.

Wang

Chen

NLRP6, decreased in gastric cancer, suppresses tumorigenicity of gastric cancer cells. Cancer Manag Res 2018; 10: 6431–6444.

62.

Okamoto

Liu

Luo

et al. Constitutively active inflammasome in human melanoma cells mediating autoinflammation via caspase-1 processing and secretion of interleukin-1beta. J Biol Chem 2010; 285: 6477–6488.

63.

Liu

Luo

Dunn

et al. Dual role of apoptosis-associated speck-like protein containing a CARD (ASC) in tumorigenesis of human melanoma. J Invest Dermatol 2013; 133: 518–527.

64.

da Silva

Oshiro

de Sá

et al. Genotyping and differential expression analysis of inflammasome genes in sporadic malignant melanoma reveal novel contribution of CARD8, IL1B and IL18 in melanoma susceptibility and progression. Cancer Genet 2016; 209: 474–480.

65.

Zhai

Liu

Kaur

et al. NLRP1 promotes tumor growth by enhancing inflammasome activation and suppressing apoptosis in metastatic melanoma. Oncogene 2017; 36: 3820–3830.

66.

Kolb

Phan

Borcherding

et al. Obesity-associated NLRC4 inflammasome activation drives breast cancer progression. Nat Commun 2016; 7: 13007.

67.

Kolb

Kluz

Tan

et al. Obesity-associated inflammation promotes angiogenesis and breast cancer via angiopoietin-like 4. Oncogene 2019; 38: 2351–2363.

68.

Weichand

Popp

Dziumbla

et al. S1PR1 on tumor-associated macrophages promotes lymphangiogenesis and metastasis via NLRP3/IL-1β. J Exp Med 2017; 214: 2695–2713.

69.

Voigt

May

Gottschlich

et al. Cancer cells induce interleukin-22 production from memory CD4+ T cells via interleukin-1 to promote tumor growth. Proc Natl Acad Sci 2017; 114: 12994–12999.

70.

Jin

Kim

HJ.

P2Y2R-mediated inflammasome activation is involved in tumor progression in breast cancer cells and in radiotherapy-resistant breast cancer. Int J Oncol 2018; 53: 1953–1966.

71.

Raut

Kim

S-H

Choi

et al. Growth of breast cancer cells by leptin is mediated via activation of the inflammasome: critical roles of estrogen receptor signaling and reactive oxygen species production. Biochem Pharmacol 2019; 161: 73–88.

72.

Kong

Wang

Zeng

et al. Differential expression of inflammasomes in lung cancer cell lines and tissues. Tumor Biol 2015; 36: 7501–7513.

73.

Sakaizawa

Matsumura

Fujii

et al. Potential role of ASC, a proapoptotic protein, for determining the cisplatin susceptibility of lung cancer cells. Tohoku J Exp Med 2018; 244: 133–144.

74.

Sorrentino

Terlizzi

Di Crescenzo

et al. Human lung cancer–derived immunosuppressive plasmacytoid dendritic cells release IL-1α in an AIM2 inflammasome-dependent manner. Am J Pathol 2015; 185: 3115–3124.

75.

Timperi

Focaccetti

Gallerano

et al. IL-18 receptor marks functional CD8⁺ T cells in non-small cell lung cancer. Oncoimmunology 2017; 6: e1328337.

76.

Lasithiotaki

Tsitoura

Samara

et al. NLRP3/Caspase-1 inflammasome activation is decreased in alveolar macrophages in patients with lung cancer. PLoS One 2018; 13: e0205242.

77.

White

The role for autophagy in cancer. J Clin Invest 2015; 125: 42–46.

78.

Sun

Gao

Loughran

et al. Caspase 1 activation is protective against hepatocyte cell death by up-regulating beclin 1 protein and mitochondrial autophagy in the setting of redox stress. J Biol Chem 2013; 288: 15947–15958.

79.

Tsapras

Nezis

IP.

Caspase involvement in autophagy. Cell Death Differ 2017; 24: 1369–1379.

80.

Chen

Ruan

Wang

et al. BAY 11-7082, a nuclear factor-κB inhibitor, induces apoptosis and S phase arrest in gastric cancer cells. J Gastroenterol 2014; 49: 864–874.

81.

Yang

C-H

Yen

T-L

Hsu

C-Y

et al. Multi-targeting andrographolide, a novel NF-κB inhibitor, as a potential therapeutic agent for stroke. Int J Mol Sci 2017; 18: 1638.

82.

Kim

M-J

Bae

G-S

I-J

et al. Fraxinellone inhibits inflammatory cell infiltration during acute pancreatitis by suppressing inflammasome activation. Int Immunopharmacol 2019; 69: 169–177.

83.

Tamura

Ishikawa

Yoshie

et al. Glibenclamide inhibits NLRP3 inflammasome-mediated IL-1β secretion in human trophoblasts. J Pharmacol Sci 2017; 135: 89–95.

84.

Zhang

Liu

Liao

et al. Potential roles of peripheral dopamine in tumor immunity. J Cancer 2017; 8: 2966–2973.

85.

Chen

Huang

C-F

Y-C

et al. Blockage of the NLRP3 inflammasome by MCC950 improves anti-tumor immune responses in head and neck squamous cell carcinoma. Cell Mol Life Sci 2018; 75: 2045–2058.

86.

Kawai

Watanabe

Yokoyama

et al. Thalidomide attenuates excessive inflammation without interrupting lipopolysaccharide-driven inflammatory cytokine production in chronic granulomatous disease. Clin Immunol 2013; 147: 122–128.

87.

McKenzie

Mamik

Saito

et al. Caspase-1 inhibition prevents glial inflammasome activation and pyroptosis in models of multiple sclerosis. Proc Natl Acad Sci 2018; 115: E6065–E6074.

88.

Ridker

MacFadyen

Thuren

et al. Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial. Lancet 2017; 390: 1833–1842.

89.

Dinarello

CA.

An interleukin-1 signature in breast cancer treated with interleukin-1 receptor blockade: implications for treating cytokine release syndrome of checkpoint inhibitors. Cancer Res 2018; 78: 5200–5202.

Insights into inflammasome and its research advances in cancer

Abstract

Keywords

Get full access to this article

References